Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy

BMC Cancer

Annamaria Ruzzo²  Vincenzo Catalano³  Emanuele Canestrari⁴  Elisa Giacomini²  Daniele Santini¹  Giuseppe Tonini¹  Bruno Vincenzi¹  Giammaria Fiorentini³  Mauro Magnani²  Francesco Graziano³ 

[1] Division of Medical Oncology, University Campus Biomedico, Rome, Italy

[2] Department of Biomolecular Sciences, University of Urbino, Urbino, Italy

[3] Division of Medical Oncology, Azienda Ospedaliera “Ospedali Riuniti Marche Nord”, Pesaro, Italy

[4] Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, Chicago, USA

关键词: Polymorphism;    Chemotherapy;    Prognosis;    Survival;    Gastric cancer;    Interleukin 6;   

Others  :  858801
DOI  :  10.1186/1471-2407-14-357

 received in 2013-09-16, accepted in 2014-05-12,  发布年份 2014

【 摘 要 】

s

Background

IL-6 triggers oncogenic/angiogenic signals and the cytokine-dependent pro-cachexia cascade. The prognostic role of the functional IL-6 (promoter) rs1800795 and the IL-6R (receptor) rs8192284 single nucleotide polymorphisms (SNP) was studied in patients with advanced gastric cancer treated with palliative chemotherapy.

Methods

One-hundred-sixty-one patients were genotyped for rs1800795 and rs8192284 SNPs using polymerase chain reaction based restriction fragment length polymorphism (PCR-RFLP) analysis assay. These results were studied for association with overall survival (OS).

Results

In 161 assessable patients, frequencies of rs1800795 G/G, G/C and C/C genotypes were 46%, 42% and 12%, respectively. Frequencies of rs8192284 A/A, A/C and C/C genotypes were 36%, 45% and 19%, respectively. Carriers of the rs1800795 G/G and rs8192284 C/C genotypes showed the worst OS. In the multivariate model, rs1800795 G/G (1.69 hazard ratio; 95% confidence interval 1.18-2.42), and rs8192284 C/C (1.78 hazard ratio; 95% confidence interval 1.12-2.83) confirmed an adverse prognostic impact.

Conclusions

In this population, genetic variants that up-regulate the IL-6 system showed impact on OS. This findings sustain the hypothesis that anti-IL-6 compounds deserve clinical studies as novel therapeutics in the palliative treatment of cancer patients.

【 授权许可】

   
2014 Ruzzo et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S: The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813, 2011:878-888.
• [2]Rose-John S: IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012, 8:1237-1247.
• [3]Tanaka T, Kishimoto T: Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 2012, 8:1227-1236.
• [4]Guo Y, Xu F, Lu T, Duan Z, Zhang Z: Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012, 38:904-910.
• [5]Sansone P, Bromberg J: Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012, 30:1005-1014.
• [6]Fearon KC, Glass DJ, Guttridge DC: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 2012, 16:153-166.
• [7]Kinoshita H, Hirata Y, Nakagawa H, Sakamoto K, Hayakawa Y, Takahashi R, Nakata W, Sakitani K, Serizawa T, Hikiba Y, Akanuma M, Shibata W, Maeda S, Koike K: Interleukin-6 mediates epithelial-stromal interactions and promotes gastric tumorigenesis. PLoS One 2013, 8:e60914.
• [8]Okamoto W, Okamoto I, Arao T, Yanagihara K, Nishio K, Nakagawa K: Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells. Br J Cancer 2011, 105:407-412.
• [9]Mejías-Luque R, Peiró S, Vincent A, Van Seuningen I, de Bolós C: IL-6 induces MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines. Biochim Biophys Acta 2008, 1783:1728-1736.
• [10]Jackson CB, Judd LM, Menheniott TR, Kronborg I, Dow C, Yeomans ND, Jackson CB, Judd LM, Menheniott TR, Kronborg I, Dow C, Yeomans ND, Boussioutas A, Robb L, Giraud AS: Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression. J Pathol 2007, 213:140-151.
• [11]Lin MT, Lin BR, Chang CC, Chu CY, Su HJ, Chen ST, Jeng YM, Kuo ML: IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer 2007, 120:2600-2608.
• [12]Howlett M, Judd LM, Jenkins B, La Gruta NL, Grail D, Ernst M, Giraud AS: Differential regulation of gastric tumor growth by cytokines that signal exclusively through the coreceptor gp130. Gastroenterology 2005, 129:1005-1018.
• [13]Huang SP, Wu MS, Shun CT, Wang HP, Lin MT, Kuo ML, Lin JT: Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 2004, 11:517-527.
• [14]Huang SP, Wu MS, Wang HP, Yang CS, Kuo ML, Lin JT: Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma. J Gastroenterol Hepatol 2002, 17:1165-1169.
• [15]Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, Kim SG, Kim SH, Jang JS, Kim MC, Kim KH, Han JY, Kim HJ: Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 2009, 9:155. BioMed Central Full Text
• [16]Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Kim HK, Ryu KW, Bae JM, Kim S: Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003, 39:184-191.
• [17]Smith AJ, Humphries SE: Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2009, 20:43-59.
• [18]Woo P, Humphries SE: IL-6 polymorphisms: a useful genetic tool for inflammation research? J Clin Invest 2013, 123:1413-1414.
• [19]Ferreira RC, Freitag DF, Cutler AJ, Howson JM, Rainbow DB, Smyth DJ, Kaptoge S, Clarke P, Boreham C, Coulson RM, Pekalski ML, Chen WM, Onengut-Gumuscu S, Rich SS, Butterworth AS, Malarstig A, Danesh J, Todd JA: Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet 2013, 9:e1003444.
• [20]Lippitz BE: Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013, 14:e218-28.
• [21]Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, Vincenzi B, Giordani P, Alessandroni P, Testa E, Tonini G, Catalano G: Second -line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 2008, 99:1402-1407.
• [22]Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, Chang JS, Lai TC, Rose-John S, Kuo ML, Wei LH: IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 2011, 71:424-434.
• [23]Waetzig GH, Rose-John S: Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin Ther Targets 2012, 16:225-236.
• [24]Van den Eynden GG, Majeed AW, Illemann M, Vermeulen PB, Bird NC, Høyer-Hansen G, Eefsen RL, Reynolds AR, Brodt P: The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res 2013, 73:2031-2043.
• [25]Li S, Wang N, Brodt P: Metastatic cells can escape the proapoptotic effects of TNF-α through increased autocrine IL-6/STAT3 signaling. Cancer Res 2012, 72:865-875.
• [26]Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, Aoki T, Ohnuma S, Aoki T: Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 2005, 8:124-131.
• [27]Hefler LA, Grimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S, Beckmann MW, Zeillinger R, Koelbl H, Tempfer CB: An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res 2003, 63:3066-3068.
• [28]DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B: Interleukin-6-174G- > C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003, 63:8051-8056.
• [29]DeMichele A, Gray R, Horn M, Chen J, Aplenc R, Vaughan WP, Tallman MS: Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Res 2009, 69:4184-4191.
• [30]Lagmay JP, London WB, Gross TG, Termuhlen A, Sullivan N, Axel A, Mundy B, Ranalli M, Canner J, McGrady P, Hall B: Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor). Clin Cancer Res 2009, 15:5234-5239.
• [31]Hohaus S, Giachelia M, Di Febo A, Martini M, Massini G, Vannata B, D’Alo’ F, Guidi F, Greco M, Pierconti F, Larocca LM, Voso MT, Leone G: Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol 2007, 18:1376-1381.
• [32]Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, Huang YJ, Wu MS: Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res 2008, 14:428-434.
• [33]Stephens OW, Zhang Q, Qu P, Zhou Y, Chavan S, Tian E, Williams DR, Epstein J, Barlogie B, Shaughnessy JD Jr: An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood 2012, 119:503-512.
• [34]Knüpfer H, Preiss R: sIL-6R: more than an agonist? Immunol Cell Biol 2008, 86:87-91.
• [35]Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV: Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012, 13:827-837.
• [36]Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK, Chung S, Luther T, Paholak HJ, Liu S, Hassan KA, Zen Q, Clouthier SG, Wicha MS: Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 2012, 47:570-584.
• [37]Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM, Hall BM: Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009, 28:2940-2947.
• [38]Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M: Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009, 115:5541-5549.
• [39]Ando K, Takahashi F, Motojima S, Nakashima K, Kaneko N, Hoshi K, Takahashi K: Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol 2013, 31:e69-72.
• [40]Hirata H, Tetsumoto S, Kijima T, Kida H, Kumagai T, Takahashi R, Otani Y, Inoue K, Kuhara H, Shimada K, Nagatomo I, Takeda Y, Goya S, Yoshizaki K, Kawase I, Tachibana I, Kishimoto T, Kumanogoh A: Favorable Responses to Tocilizumab in Two Patients With Cancer-Related Cachexia. J Pain Symptom Manage 2013, 46:e9-e13.
• [41]Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F: A Phase I, Open-Label Study of Siltuximab, anAnti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease. Clin Cancer Res 2013, 19:3659-3670.
• [42]Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA, Reddy M, Cornfeld M, Eisenberger M: A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 2013, 31:669-676.
• [43]Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 2011, 11:1663-1668.